Rohto Pharmaceutical Co (RPHCF) Stock Statistics & Valuation Metrics

Rohto Pharmaceutical Co has a market cap or net worth of $4.03B. The enterprise value is $531.68B.

Market Cap

$4.03B

Enterprise Value

$531.68B

Rohto Pharmaceutical Co has 236,178,310 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

236,178,310

Owned by Insiders

―

Owned by Institutions

19.60%

Rohto Pharmaceutical Co’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 7.61%.

Return on Equity (ROE)

0.11

Return on Assets (ROA)

0.07

Return on Invested Capital (ROIC)

7.61%

Return on Capital Employed (ROCE)

0.11

Revenue Per Employee

36.99M

Profits Per Employee

3.69M

Employee Count

9,292

Asset Turnover

0.71

Inventory Turnover

2.45

The current PE Ratio of Rohto Pharmaceutical Co is 18.55. Rohto Pharmaceutical Co’s PEG ratio is -6.06.

PE Ratio

18.55

PS Ratio

1.74

PB Ratio

1.99

Price to FCF

0.00

Price to Operating Cash Flow

0.00

PEG Ratio

-6.06

In the last 12 months, Rohto Pharmaceutical Co had revenue of 343.73B and earned 34.25B in profits. Earnings per share was 151.56.

Revenue

343.73B

Gross Profit

182.96B

Operating Income

40.71B

Pretax Income

46.82B

Net Income

34.25B

EBITDA

65.48B

Earnings Per Share (EPS)

151.56

In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.

Operating Cash Flow

0

Free Cash Flow

0

Free Cash Flow per Share

0.00

Rohto Pharmaceutical Co pays an annual dividend of $0.15, resulting in a dividend yield of 2.21%

Dividend Per Share

$0.15

Dividend Yield

2.21%

Payout Ratio

47.65%

Free Cash Flow Yield

0.00%

Earnings Yield

5.39%

Beta

0.18

52-Week Price Change

15.76%

50-Day Moving Average

16.60

200-Day Moving Average

15.46

Relative Strength Index (RSI)

45.01

Average Volume (3m)

738

Rohto Pharmaceutical Co upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).

Last Earnings Date

Aug 06, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

Sep 29, 2026

Rohto Pharmaceutical Co as a current ratio of 2.04, with Debt / Equity ratio of 19.96%

Current Ratio

2.04

Quick Ratio

1.48

Debt to Market Cap

0.10

Net Debt to EBITDA

-0.41

Interest Coverage Ratio

31.70

In the past 12 months, Rohto Pharmaceutical Co has paid 12.40B in taxes.

Income Tax

12.40B

Effective Tax Rate

0.26

Rohto Pharmaceutical Co EV to EBITDA ratio is 9.16, with an EV/FCF ratio of 0.00.

EV to Sales

1.66

EV to EBITDA

9.16

EV to Free Cash Flow

0.00

EV to Operating Cash Flow

0.00

Rohto Pharmaceutical Co has $84.77B in cash and marketable securities with $58.10B in debt, giving a net cash position of $26.67B billion.

Cash & Marketable Securities

$84.77B

Total Debt

$58.10B

Net Cash

$26.67B

Net Cash Per Share

$112.92

Tangible Book Value Per Share

$1,081.71

Gross margin is 55.56%, with operating margin of 12.10%, and net profit margin of 9.38%.

Gross Margin

55.56%

Operating Margin

12.10%

Pretax Margin

13.17%

Net Profit Margin

9.38%

EBITDA Margin

18.16%

EBIT Margin

13.12%

The average price target for Rohto Pharmaceutical Co is $21.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$21.25

Price Target Upside

24.69% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

6.22%

EPS Growth Forecast

-6.55%